	Application No.	Applicant(s)
Notice of Allowability	•	
	10/632,694 Examiner	ALLISON, ANTHONY Art Unit
	Lammer	Art omt
	Sheridan K Snedden	1653
The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI- of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in t or other appropriate commun GHTS. This application is su	his application. If not included ication will be mailed in due course. THIS
1. This communication is responsive to <u>9/27/2004</u> .		
2. The allowed claim(s) is/are <u>1,6-10 and 16-20</u> .		
3. The drawings filed on 27 September 2004 and 01 August 2003 are accepted by the Examiner.		
 4. Acknowledgment is made of a claim for foreign priority un a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 	been received. been received in Application	No
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
6. CORRECTED DRAWINGS (as "replacement sheets") musi	t be submitted.	
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
 DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. 		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5 Notice of Info	mal Patent Application (PTO-152)
Notice of Neterences Cited (FTO-092) Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Sun	, , , , , , , , , , , , , , , , , , , ,
3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08	Paper No./M	ail Date mendment/Comment
Paper No./Mail Date 8/6/2004, 4/19/2004	_	
4. Examiner's Comment Regarding Requirement for Deposit		atement of Reasons for Allowance
of Biological Material	9. Other	
		,

1. This Office Action is in response to Paper filed 9/27/2004. Claims 2-5 have been

canceled. Applicant's amendment of claims 1, 6-10 is acknowledged. Applicant's addition of

new claims 16-20 is acknowledged. Claims 1, 6-10 and 16-20 are under examination.

2. All objections and/or rejections are withdrawn.

3. An examiner's amendment to the record appears below. Should the changes and/or

additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR

1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the

payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with

Darla Yoerg on October 25, 2004.

4. The application has been amended as follows:

Cancel claims 11-15

Claim 1 (currently amended). A method for treating sickle-cell disease in a subject,

comprising administering to said subject a pharmaceutical composition comprising a

therapeutically effective amount of a modified annexin protein, wherein said modified

annexin protein comprises a first annexin protein coupled to a second annexin protein,

wherein the sickle-cell disease is treated.

Application/Control Number: 10/632,694

Art Unit: 1653

Claim 20 (currently amended). A method for treating sickle-cell disease in a subject, comprising administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of a modified annexin protein, wherein said modified annexin protein comprises an annexin V protein coupled to at least one additional annexin V protein, wherein said isolated modified annexin protein comprises an amino acid sequence selected from the group consisting of:

- a) SEQ ID NO:6; and
- b) an amino acid sequence having at least 95% sequence identity to SEQ ID NO:6,

wherein the sickle-cell disease is treated.

Conclusion

5. Claims 1, 6-10 and 16-20 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sheridan K Snedden whose telephone number is (703) 305-4843. The examiner can normally be reached on Monday - Friday, 8:30 AM to 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on (571) 272-0925. The fax phone number for regular communications to the organization where this application or proceeding is assigned is (703) 872-9306.

Application/Control Number: 10/632,694

Art Unit: 1653

Page 4

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

SKS

October 28, 2004

SVS

JON WEBER
SUPERVISORY PATENT EXAMINER